In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial-Reference-Cited by-同舟云学术

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial

Published:2020-03-20 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Rosás-Umbert Miriam,Ruiz-Riol Marta,Fernández Marco A.,Marszalek Marta,Coll Pep,Manzardo Christian,Cedeño Samandhy,Miró José M.,Clotet Bonaventura,Hanke Tomáš,Moltó José,Mothe Beatriz,Brander Christian,

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference45 articles.

1. CD4+ count-guided interruption of antiretroviral treatment;El-Sadr;N Engl J Med,2006

2. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects;Buzón;Nat Med,2010

3. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study;Llibre;Antivir Ther,2011

4. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on t cells latently infected;Gutiérrez;PLoS ONE,2011

5. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients;Vallejo;AIDS,2012

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells;Antiviral Research;2024-08

2. High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells;Scientific Reports;2024-06-17

3. Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination;eBioMedicine;2023-09

4. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases;Journal of Molecular Biology;2023-08

5. Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials;The Brazilian Journal of Infectious Diseases;2023-05